DMXAA: An antivascular agent with multiple host responses

International Journal of Radiation Oncology Biology Physics

Volumn 54, Issue 5, 2002, Pages 1503-1511

  Baguley, Bruce C ^a   Ching, Lai Ming ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Antivascular; Immunomodulation; Nitric oxide; Serotonin; Tumor necrosis factor

Indexed keywords

CARBOXYLIC ACIDS; CELLS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; OPTIMIZATION; TOXICITY; TUMORS;

ANTIVASCULAR AGENTS;

ONCOLOGY;

5 HYDROXYINDOLEACETIC ACID; 5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; NITRIC OXIDE; SEROTONIN; TUMOR NECROSIS FACTOR RECEPTOR 1;

BLOOD LEVEL; CANCER GROWTH; CLINICAL TRIAL; COLON CARCINOMA; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; IMMUNE RESPONSE; KNOCKOUT MOUSE; MEASUREMENT; MITOSIS; MOUSE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SEROTONIN RELEASE; TUMOR NECROSIS;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; HYDROXYINDOLEACETIC ACID; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MODELS, BIOLOGICAL; MODELS, CHEMICAL; NECROSIS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE; RECEPTORS, TUMOR NECROSIS FACTOR; SEROTONIN; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; XANTHENES; XANTHONES;

EID: 0036891050     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(02)03920-2     Document Type: Conference Paper

References (77)

1. Denekamp J. Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev. 9:1990;267-282.
2. Hobohm U. Fever and cancer in perspective. Cancer Immunol Immunother. 50:2001;391-396.
3. Starnes C.O. Coley's toxins in perspective. Nature. 357:1992;11-12.
4. MacPherson G.G., North R.J. Endotoxin-mediated necrosis and regression of established tumours in the mouse. A correlative study of quantitative changes in blood flow and ultrastructural morphology. Cancer Immunol Immunother. 21:1986;209-216.
5. Old L.J. Tumor necrosis factor (TNF). Science. 230:1985;630-632.
6. Carswell E.A., Old L.J., Kassel R.L., et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A. 25:1975;3666-3670.
7. Pimm M.V., Gribben S.J., Morris T.M. Influence of recombinant tumour necrosis factor-alpha on blood flow and antibody localisation in human tumour xenografts in nude mice. J Cancer Res Clin Oncol. 117:1991;543-548.
8. Yi E.S., Ulich T.R. Endotoxin, interleukin-1, and tumor necrosis factor cause neutrophil-dependent microvascular leakage in postcapillary venules. Am J Pathol. 140:1992;659-663.
9. Lienard D., Ewalenko P., Delmotte P., et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol. 10:1992;52-60.
10. Atassi G., Briet P., Berthelon J.-J., et al. Synthesis and antitumor activity of some 8-substituted 4-oxo-4H-1-benzopyrans. Eur J Med Chem. 5:1985;393-402.
11. Plowman J., Narayanan V.L., Dykes D., et al. Flavone acetic acid A novel agent with preclinical antitumor activity against colon adenocarcinoma 38 in mice . Cancer Treat Rep. 70:1986;631-638.
12. Smith G.P., Calveley S.B., Smith M.J., et al. Flavone acetic acid (NSC 347512) induces haemorrhagic necrosis of mouse colon 26 and 38 tumours. Eur J Cancer Clin Oncol. 23:1987;1209-1212.
13. Baguley B.C., Calveley S.B., Crowe K.K., et al. Comparison of the effects of flavone acetic acid, fostriecin, homoharringtonine and tumour necrosis factor alpha on Colon 38 tumors in mice. Eur J Cancer Clin Oncol. 25:1989;263-269.
14. Ching L.-M., Baguley B.C. Induction of natural killer cell activity by the antitumour compound flavone acetic acid (NSC 347512). Eur J Cancer Clin Oncol. 23:1987;1047-1050.
15. Evelhoch J.L., Bissery M.-C., Chabot G.G., et al. Flavone acetic acid (NSC 347512)-induced modulation of murine tumor physiology monitored by in vivo nuclear magnetic resonance spectroscopy. Cancer Res. 48:1988;4749-4755.
16. Bibby M.C., Double J.A., Loadman P.M., et al. Reduction of tumor blood flow by flavone acetic acid A possible component of therapy . J Natl Cancer Inst. 81:1989;216-220.
17. Zwi L.J., Baguley B.C., Gavin J.B., et al. Blood flow failure as a major determinant in the antitumor action of flavone acetic acid (NSC 347512). J Natl Cancer Inst. 81:1989;1005-1013.
18. Mace K.F., Hornung R.L., Wiltrout R.H., et al. Correlation between in vivo induction of cytokine gene expression by flavone acetic acid and strict dose dependency and therapeutic efficacy against murine renal cancer. Cancer Res. 50:1990;1742-1747.
19. Rewcastle G.W., Atwell G.J., Zhuang L., et al. Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. J Med Chem. 34:1991;217-222.
20. Pedley R.B., Boden J.A., Boden R., et al. Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flow-modifying agents. Cancer Res. 56:1996;3293-3300.
21. Zwi L.J., Baguley B.C., Gavin J.B., et al. Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents. Oncol Res. 6:1994;79-85.
22. Lash C.J., Li A.E., Rutland M., et al. Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br J Cancer. 78:1998;439-445.
23. Pedley R.B., Sharma S.K., Boxer G.M., et al. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent. Cancer Res. 59:1999;3998-4003.
24. Siim B.G., Laux W.T., Rutland M.D., et al. Scintigraphic imaging of the hypoxia marker (99m)Technetium-labeled 2,2′-(1,4-diaminobutane)bis(2-methyl-3-butanone) dioxime (Tc-99m-labeled HL-91; Prognox) Noninvasive detection of tumor response to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid . Cancer Res. 60:2000;4582-4588.
25. Thomsen L.L., Ching L.M., Zhuang L., et al. Tumor-dependent increased plasma nitrate concentrations as an indication of the antitumor effect of flavone-8-acetic acid and analogues in mice. Cancer Res. 51:1991;77-81.
26. Baguley B.C., Zhuang L., Kestell P. Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicine - relation to vascular effects. Oncol Res. 9:1997;55-60.
27. Philpott M., Baguley B.C., Ching L.-M. Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol. 36:1995;143-148.
28. Zhao L., Kestell P., Ching L.-M., et al. Oral activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice. Cancer Chemother Pharmacol. 49:2002;20-26.
29. Kestell P., Zhao L., Jameson M., et al. Measurement of plasma 5-hydroxyindoleacetic acid as a possible clinical surrogate marker for the action of antivascular agents. Clin Chim Acta. 314:2001;159-166.
30. Rewcastle G.W., Atwell G.J., Baguley B.C., et al. Potential antitumor agents. 58. Synthesis and structure-activity relationships of substituted xanthenone-4-acetic acids active against the Colon 38 tumor in vivo. J Med Chem. 32:1989;793-799.
31. Rewcastle G.W., Atwell G.J., Palmer B.D., et al. Potential antitumor agents. 62. Structure activity relationships for tricyclic compounds related to the colon tumor active drug 9-oxo-9H-xanthene-4-acetic acid. J Med Chem. 34:1991;491-496.
32. Gamage S.A., Rewcastle G.W., Atwell G.J., et al. Structure-activity relationships for substituted 9-oxo-9, 10-dihydroacridine-4-acetic acids - analogues of the colon tumour active agent xanthenone-4-acetic acid. Anticancer Drug Des. 7:1992;403-414.
33. Baguley B.C., Holdaway K.M., Thomsen L.L., et al. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine - evidence for a vascular mechanism. Eur J Cancer. 27:1991;482-487.
34. Ludford R.J. Colchicine in the experimental chemotherapy of cancer. J Natl Cancer Inst. 6:1945;411-441.
35. Hill S.A., Lonergan S.J., Denekamp J., et al. Vinca alkaloids - anti-vascular effects in a murine tumour. Eur J Cancer. 29A:1993;1320-1324.
36. Hill S.A., Lonergan S.J., Denekamp J., et al. The effect of Vinca alkaloids on tumour blood flow. Adv Exp Med Biol. 345:1994;417-422.
37. Dark G.G., Hill S.A., Prise V.E., et al. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. 57:1997;1829-1834.
38. Ching L.-M., Finlay G.J., Joseph W.R., et al. In vitro methods for screening agents with an indirect mechanism of antitumour activity Xanthenone analogues of flavone acetic acid . Eur J Cancer. 27:1991;1684-1689.
39. Cao Z., Joseph W.R., Browne W.L., et al. Thalidomide increases both intra-tumoural tumour necrosis factor-α production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer. 80:1999;716-723.
40. Ching L.M., Joseph W.R., Crosier K.E., et al. Induction of tumor necrosis factor-alpha messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4-acetic acid (NSC 640488). Cancer Res. 54:1994;870-872.
41. Philpott M., Ching L.M., Baguley B.C. The antitumour agent 5,6-dimethylxanthenone-4-acetic acid acts in vitro on human mononuclear cells as a co-stimulator to other inducers of tumour necrosis factor. Eur J Cancer. 37:2001;1930-1937.
42. Kerr D.J., Kaye S.B. Flavone acetic acid - preclinical and clinical activity. Eur J Cancer Clin Oncol. 25:1989;1271-1272.
43. Rustin G., Galbraith S., Taylor N., et al. Impact on tumour perfusion measured by dynamic magnetic resonance imaging (MRI), in the phase 1 trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Ann Oncol. 9:1998;126.
44. Jameson M.B., Thompson P.I., Baguley B.C., et al. Phase I pharmacokinetic and pharmacodynamic study of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Proc Am Soc Clin Oncol. 19:2000;182a.
45. Manda T., Nishigaki F., Mori J., et al. Important role of serotonin in the antitumor effects of tumor necrosis factor-alpha in mice. Cancer Res. 48:1988;4250-4255.
46. Baguley B.C., Cole G., Thomsen L.L., et al. Serotonin involvement in the antitumour and host effects of flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol. 33:1993;77-81.
47. Baguley B.C. Small-molecule cytokine inducers causing tumor necrosis. Curr Opin Investig Drugs. 2:2001;967-975.
48. Zhao L., Baguley B.C., Kestell P., et al. The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice. Br J Cancer. 2002;. in press.
49. Palmer R.M.J., Ferrige A.G., Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 327:1987;524-526.
50. Veszelovszky E., Holford N.H.G., Thomsen L.T., et al. Plasma nitrate clearance in mice Modelling of the systemic production of nitrate following the induction of nitric oxide synthesis . Cancer Chemother Pharmacol. 36:1995;155-159.
51. Baguley B.C., Thomsen L.L., Ching L.-M. Evidence that the 5-hydroxytryptamine antagonist cyproheptadine modulates nitric oxide production in mice in response to flavone acetic acid, vinblastine and other agents. Moncada S., Marletta M.A., Hibbs J.B. Jr, et al. Biology of nitric oxide. Part 2. Enzymology, Biochemistry and Immunology. 1992;222 Portland Press, London.
52. Feng D., Nagy J.A., Dvorak A.M., et al. Different pathways of macromolecule extravasation from hyperpermeable tumor vessels. Microvasc Res. 59:2000;24-37.
53. Jain R.K. Determinants of tumor blood flow A review . Cancer Res. 48:1988;2641-2658.
54. Milosevic M.F., Fyles A.W., Hill R.P. The relationship between elevated interstitial fluid pressure and blood flow in tumors A bioengineering analysis . Int J Radiat Oncol Biol Phys. 43:1999;1111-1123.
55. Royall J.A., Berkow R.L., Beckman J.S., et al. Tumor necrosis factor and interleukin 1-alpha increase vascular endothelial permeability. Am J Physiol. 257:1989;L399-L410.
56. Ching L.-M., Xu Z.-F., Gummer B.H., et al. Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer. 72:1995;339-343.
57. Joseph W.R., Cao Z., Mountjoy K.G., et al. Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid A novel approach to cancer therapy . Cancer Res. 59:1999;633-638.
58. Ching L.M., Goldsmith D., Joseph W.R., et al. Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice. Cancer Res. 59:1999;3304-3307.
59. Dvorak H.F., Gresser I. Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice. J Natl Cancer Inst. 81:1989;497-502.
60. Pang J.-H., Cao Z., Joseph W.R., et al. Antitumour activity of the novel immune modulator 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice lacking the interferon-gamma receptor. Eur J Cancer. 34:1998;1282-1289.
61. Jenkins D.C., Wilkinson J., Lindon J.C., et al. Anti-tumour effects of 5-hydroxytryptamine (5-HT) are not entirely attributable to its effects on tumour vasculature. Int J Radiat Biol. 60:1991;243-248.
62. Stücker O., Vicaut E., Teisseire B. Specific response to 5-HT2 agonists by arterioles linked to Meth A tumors in mice. Am J Physiol. 262:1992;H704-H709.
63. Feng D., Nagy J.A., Hipp J., et al. Vesiculo-vacuolar organelles and the regulation of venule permeability to macromolecules by vascular permeability factor, histamine, and serotonin. J Exp Med. 183:1996;1981-1986.
64. Dvorak A.M., Feng D. The vesiculo-vacuolar organelle (VVO). A new endothelial cell permeability organelle. J Histochem Cytochem. 49:2001;419-432.
65. Zhao L., Kestell P., Philpott M., et al. Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother Pharmacol. 47:2001;491-497.
66. Fukumura D., Jain R.K. Role of nitric oxide in angiogenesis and microcirculation in tumors. Cancer Metastasis Rev. 17:1998;77-89.
67. Thomsen L.L., Baguley B.C., Wilson W.R. Nitric oxide Its production in host-cell-infiltrated EMT6 spheroids and its role in tumour cell killing by flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid . Cancer Chemother Pharmacol. 31:1992;151-155.
68. Ching L.-M., Cao Z., Kieda C., et al. Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer. 86:2002;1937-1942.
69. Ching L.M., Joseph W.R., Baguley B.C. Antitumour responses to flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid in immune deficient mice. Br J Cancer. 66:1992;128-130.
70. Yin M.J., Yamamoto Y., Gaynor R.B. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I kappa B kinase-beta. Nature. 396:1998;77-80.
71. Chaplin D.J., Pettit G.R., Parkins C.S., et al. Antivascular approaches to solid tumour therapy - evaluation of tubulin binding agents. Br J Cancer. 74:1996;S86-S88.
72. Baguley B.C., Wilson W.R. Potential of DMXAA combination therapy for solid tumors. Expert Rev Anticancer Ther. 2002;. in press.
73. Wilson W.R., Li A.E., Cowan D.S.M., et al. Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Int J Radiat Oncol Biol Phys. 42:1998;905-908.
74. Murata R., Siemann D.W., Overgaard J., et al. Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid. Radiat Res. 156:2001;503-509.
75. Wilson W.R., Baguley B.C. Combination of the antivascular agent DMXAA with radiation and chemotherapy. Int J Radiat Oncol Biol Phys. 46:2000;706.
76. Cliffe S., Taylor M.L., Rutland M., et al. Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid. Int J Radiat Oncol Biol Phys. 29:1994;373-377.
77. Kanwar J.R., Kanwar R.K., Pandey S., et al. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci. Cancer Res. 61:2001;1948-1956.